Healthcare | August 21, 2024
Antara AGEasy celebrates one year of advancing senior health solutions
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Strong topline growth driven by solid performance across key brands.
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
